GlobeNewsWire
14 Aug 2026, 12:45 UTC · 4w ago
Verdict
Headline takes no side. We score VVOS +0.00 across two claims — neutral.
+0.00neutral
Near neutral — 90% of ticker scores this week are stronger
What the story claims
2 claims · scored −1 bearish … +1 bullish
Vivos Therapeutics management will provide updates on strategic collaborations and their expected impact on near-term revenue growth and cash burn during today's call.
So whatDetails on revenue acceleration and cash runway are the primary drivers of valuation for small-cap medical device companies.
More positive than 77% of claims this week
Vivos Therapeutics is scheduled to release its second quarter 2026 financial results after market close on Friday, August 14, 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 45% of claims this week
Which stocks this story touches
Near neutral — 90% of ticker scores this week are stronger
The article is a routine announcement scheduling the release of financial results and a conference call.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
9h ago
—
No price for VVOS right now — the quote feed didn't answer.
VVOS chart →
